Skip to content
DataLookout
Menu

LM11A31HANDNCT07934186

LM11A-31 Safety and Tolerability in Aging People Living With HIV and Neurocognitive Impairment

StatusNot Yet Recruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria changed
    • Secondary endpoints: details revised at 8 of 8 entries
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Adverse effects (AE)
Timeframe: From enrollment until the end of treatments at 48 weeks
Cluster of Differentiation (CD4)+ T cells
Timeframe: From enrollment until the end of treatments at 48 weeks
HIV-1 ribonucleic acid (RNA)
Timeframe: From enrollment until the end of treatments at 48 weeks
Neurocognitive performance
Timeframe: From enrollment until the end of treatments at 48 weeks
Number of Participants with Depressive symptoms or suicidal ideation
Timeframe: From enrollment until the end of treatments at 48 weeks

Secondary (8)

Change in Expression of the Biomarker Neurofilament light chain (NFL)
Change in expression of the biomarker Neurogranin
Change in expression of the biomarker Synaptosomal Protein-25 (SNAP-25)
Change in Expression of the Biomarker phosphoThreonine 181 Tau (pThr181 Tau)
48-plex cytokine array
Show 3 moreShow less
Change in expression of the biomarker C-X-C Motif Chemokine Ligand 10 (CXCL10)
Change in expression of the biomarkerChitinase-3-like protein 1 (YKL-40)
Change in expression of the biomarker Amyloid beta 1-42 (Aβ1-42)

Arms and interventions

LM11A-31, followed by PlaceboActive comparator

LM11A-31 administered orally in the form of tablets for 24 weeks. Then placebo oral tablets identical to the active compound taken for 24 weeks.

Placebo, followed by LM11A-31Placebo comparator

Placebo oral tablets identical to the active compound taken for 24 weeks. Then LM11A-31 administered orally in the form of tablets for 24 weeks.

Drugs: LM11A-31, Placebo

Sites

1 site in 1 country

  • University of North Carolina School of Medicine, Clinical and Translational Research CenterUnitChapel Hill, North Carolina, United States